Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 12, 2013, Pages 1843-1852

  Van Vliet, Esther I ^a   De Herder, Wouter W ^a   De Rijke, Yolanda B ^a   Zillikens, M Carola ^a   Kam, Boen L R ^a   Teunissen, Jaap J M ^a   Peeters, Robin P ^a   Krenning, Eric P ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hypocalcaemia; Neuroendocrine tumour; Side effects

Indexed keywords

AMINO ACID; AMINO TERMINAL TELOPEPTIDE; ARGININE; BIOCHEMICAL MARKER; CALCIUM; CAPECITABINE; CARBOXY TERMINAL TELOPEPTIDE; GRANISETRON; INTERFERON; LUTETIUM 177; LYSINE; MAGNESIUM; OCTREOTIDE[3 TYROSINE]; PARATHYROID HORMONE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TETRAXETAN; TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; UNCLASSIFIED DRUG; VITAMIN D; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; BIOLOGICAL MARKER; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; FEMALE; HORMONE DETERMINATION; HUMAN; HYPOCALCEMIA; KIDNEY FUNCTION; LABORATORY TEST; LIVER METASTASIS; MALE; NAUSEA; NEUROENDOCRINE TUMOR; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PROSPECTIVE STUDY; RADIATION DOSE; RADIOISOTOPE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; URINE LEVEL; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCIUM; FEMALE; HUMANS; HYPOCALCEMIA; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS;

EID: 84888005187     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2503-y     Document Type: Article

References (15)

1. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12(7):941-5.
2. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43(5):610-6.
3. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30(2):207-16.
4. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147-56.
5. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30.
6. Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, et al. Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging. 2009;36(11):1758-66.
7. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0),Tyr(3)- octreotate. J Nucl Med. 2005;46 Suppl 1:83S-91S.
8. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847-56.
9. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416-23.
10. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319-25.
11. Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, et al. Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept. 2007;138(1):32-9.
12. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53-73.
13. Glazebrook GA. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987;154(4):368-73.
14. Guven A, Salman S, Boztepe H, Yarman S, Tanakol R, Azizlerli H, et al. Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer. Ann Nucl Med. 2009;23(5):437-41.
15. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm. 2006;63(5):419-30.